Association of the EGF-TM7 receptor CD97 expression with FLT3-ITD in acute myeloid leukemia

Internal tandem duplications within the juxtamembrane region of the FMS-like tyrosine kinase receptor FLT3 (FLT3-ITD) represents one of the most common mutations in patients with acute myeloid leukemia (AML) which results in constitutive aberrant activation, increased proliferation of leukemic progenitors and is associated with an aggressive clinical phenotype. The expression of CD97, an EGF-TM7 receptor, has been linked to invasive behavior in thyroid and colorectal cancer. Here, we have investigated the association of CD97 with FLT3-ITD and its functional consequences in AML. Higher CD97 expression levels have been detected in 208 out of 385 primary AML samples. This was accompanied by a significantly increased bone marrow blast count as well as by mutations in the FLT3 gene. FLT3-ITD expressing cell lines as MV4-11 and MOLM-13 revealed significantly higher CD97 levels than FLT3 wildtype EOL-1, OCI-AML3 and HL-60 cells which were clearly decreased by the tyrosine kinase inhibitors PKC412 and SU5614. CD97 knock down by short hairpin RNA in MV4-11 cells resulted in inhibited trans-well migration towards fetal calf serum (FCS) and lysophosphatidic acid (LPA) being at least in part Rho-A dependent. Moreover, knock down of CD97 led to an altered mechanical phenotype, reduced adhesion to a stromal layer and lower wildtype FLT3 expression. Our results, thus, constitute the first evidence for the functional relevance of CD97 expression in FLT3-ITD AML cells rendering it a potential new theragnostic target.

[1]  U. Keyser,et al.  Real-time deformability cytometry: on-the-fly cell mechanical phenotyping , 2015, Nature Methods.

[2]  C. Desterke,et al.  SP/drug efflux functionality of hematopoietic progenitors is controlled by mesenchymal niche through VLA-4/CD44 axis , 2014, Leukemia.

[3]  E. Anaissie,et al.  MicroRNA theragnostics for the clinical management of multiple myeloma , 2014, Leukemia.

[4]  M. Konopleva,et al.  Advances in understanding the leukaemia microenvironment , 2014, British journal of haematology.

[5]  M. Ivan,et al.  CD97 is a multifunctional leukocyte receptor with distinct roles in human cancers (Review). , 2013, International journal of oncology.

[6]  E. Mejstrikova,et al.  Leukemia surfaceome analysis reveals new disease-associated features. , 2013, Blood.

[7]  B. Brors,et al.  Autotaxin is expressed in FLT3-ITD positive acute myeloid leukemia and hematopoietic stem cells and promotes cell migration and proliferation. , 2013, Experimental hematology.

[8]  E. Vellenga,et al.  A Proteomics and Transcriptomics Approach to Identify Leukemic Stem Cell (LSC) Markers* , 2012, Molecular & Cellular Proteomics.

[9]  Jochen Guck,et al.  Viscoelastic Properties of Differentiating Blood Cells Are Fate- and Function-Dependent , 2012, PloS one.

[10]  G. Aust,et al.  Thy-1 (CD90) Is an Interacting Partner for CD97 on Activated Endothelial Cells , 2012, The Journal of Immunology.

[11]  M. Raffeld,et al.  LPA receptor heterodimerizes with CD97 to amplify LPA-initiated RHO-dependent signaling and invasion in prostate cancer cells. , 2011, Cancer research.

[12]  T. van der Poll,et al.  A Novel Role for CD55 in Granulocyte Homeostasis and Anti-Bacterial Host Defense , 2011, PloS one.

[13]  Elaine Coustan-Smith,et al.  New markers for minimal residual disease detection in acute lymphoblastic leukemia. , 2011, Blood.

[14]  Shinichirou Takahashi.  Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications , 2011, Journal of hematology & oncology.

[15]  Stefan Schinkinger,et al.  The regulatory role of cell mechanics for migration of differentiating myeloid cells , 2009, Proceedings of the National Academy of Sciences.

[16]  M. Konopleva,et al.  Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches. , 2009, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[17]  W. Fibbe,et al.  CD97 is differentially expressed on murine hematopoietic stem-and progenitor-cells , 2008, Haematologica.

[18]  M. Kwakkenbos,et al.  Differential role of CD97 in interleukin-8-induced and granulocyte-colony stimulating factor-induced hematopoietic stem and progenitor cell mobilization , 2008, Haematologica.

[19]  Daniel A Fletcher,et al.  Chemotherapy exposure increases leukemia cell stiffness. , 2007, Blood.

[20]  Markus Loeffler,et al.  Tumorigenesis and Neoplastic Progression Individual Cell-Based Models of Tumor-Environment Interactions Multiple Effects of CD 97 on Tumor Invasion , 2006 .

[21]  H. Broxmeyer,et al.  Flt3 ligand and the Flt3 receptor regulate hematopoietic cell migration by modulating the SDF-1alpha(CXCL12)/CXCR4 axis. , 2005, Blood.

[22]  W. Stetler-Stevenson,et al.  CD97, an adhesion receptor on inflammatory cells, stimulates angiogenesis through binding integrin counterreceptors on endothelial cells. , 2005, Blood.

[23]  S. Gordon,et al.  Expression of the largest CD97 and EMR2 isoforms on leukocytes facilitates a specific interaction with chondroitin sulfate on B cells , 2005, Journal of leukocyte biology.

[24]  A. Trautmann,et al.  ERM proteins regulate cytoskeleton relaxation promoting T cell–APC conjugation , 2004, Nature Immunology.

[25]  John Q. Davies,et al.  The epidermal growth factor-like domains of the human EMR2 receptor mediate cell attachment through chondroitin sulfate glycosaminoglycans. , 2003, Blood.

[26]  W. Hiddemann,et al.  Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  G. Aust,et al.  Expression and regulation of CD97 in colorectal carcinoma cell lines and tumor tissues. , 2002, The American journal of pathology.

[28]  G. Ehninger,et al.  Analysis of Flt3-activating Mutations in 979 Patients with Acute Myelogenous Leukemia: Association with Fab Subtypes and Identification of Subgroups with Poor Prognosis , 2022 .

[29]  H. Kantarjian,et al.  Acute myeloid leukemia , 2018, Methods in Molecular Biology.

[30]  G. Aust,et al.  Expression characteristics of the human CD97 antigen. , 1997, Tissue antigens.

[31]  W. Scherbaum,et al.  CD97: a dedifferentiation marker in human thyroid carcinomas. , 1997, Cancer research.

[32]  R. V. van Lier,et al.  The seven-span transmembrane receptor CD97 has a cellular ligand (CD55, DAF) , 1996, The Journal of experimental medicine.